Company Encyclopedia
View More
name
Strata Skin Sciences
SSKN.US
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, and other skin conditions; and TheraClear acne therapy system for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. It serves dermatologists and dermatological group clinics.
1.407 T
SSKN.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking142/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-204.07%E
    • Profit Margin-35.10%E
    • Gross Margin60.38%A
  • Growth ScoreD
    • Revenue YoY-5.19%D
    • Net Profit YoY-16.61%D
    • Total Assets YoY-23.60%E
    • Net Assets YoY-85.94%E
  • Cash ScoreD
    • Cash Flow Margin-284.90%D
    • OCF YoY-5.19%D
  • Operating ScoreB
    • Turnover0.87B
  • Debt ScoreE
    • Gearing Ratio95.72%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Director Samuel Rubinstein Reports Sale of STRATA Skin Sciences Inc. Common Shares

    Samuel Rubinstein, Director at STRATA Skin Sciences Inc., reported the sale of common shares of the company. The original filing is available via EDGAR, the SEC's system. This news brief was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    SSKN
    +3.55%
    Reuters·
    US
    SSKN
    +3.55%

    Maxim Group Sticks to Its Buy Rating for Strata Skin Sciences (SSKN)

    Maxim Group analyst Anthony Vendetti maintained a Buy rating on Strata Skin Sciences, with shares closing at $1.36. Vendetti, who covers the Healthcare sector, has an average return of -25.0% and a 24.60% success rate. The general consensus is a Moderate Buy for Strata Skin Sciences, with a $4.00 average price target.

    Tip Ranks·
    US
    SSKN
    +3.55%
    Tip Ranks·
    US
    SSKN
    +3.55%

    Strata Skin Sciences Earnings Call: Mixed Sentiment Amid Market Expansion

    Strata Skin Sciences' Q3 earnings call revealed mixed sentiment. The company expanded its market and achieved litigation success but faced revenue declines due to international trade challenges. Key highlights include the expansion of CPT codes for the XTRAC laser, success of the Elevate360 program, and international expansion efforts. Despite a 20% revenue decline, Strata maintained a 60% gross profit margin and expressed optimism for future growth through strategic initiatives.

    Tip Ranks·
    US
    SSKN
    +3.55%
    Tip Ranks·
    US
    SSKN
    +3.55%

    Strata Skin Sciences | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 6.929 M

    LB filings·
    US
    SSKN
    +3.55%
    LB filings·
    US
    SSKN
    +3.55%

    STRATA Skin Sciences Reports Q3 2025 Financial Results

    STRATA Skin Sciences reported its Q3 2025 financial results, highlighting progress in reimbursement codes, regulatory clearance in Mexico, and clinical validations. Despite these advancements, total revenue fell by 21% due to a 60% drop in equipment revenue. The company posted a net loss of $1.6 million, an improvement from last year's $2.1 million loss. STRATA is optimistic about future growth, focusing on cost management, market expansion, and leveraging new reimbursement opportunities.

    Tip Ranks·
    US
    SSKN
    +3.55%
    Tip Ranks·
    US
    SSKN
    +3.55%
    © 2025 Longbridge｜Disclaimer